Skip to main content

Advertisement

SpringerLink
Log in

Response to: The evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder is in fact flawed

  • Letter to the Editor
  • Published:
European Child & Adolescent Psychiatry Aims and scope Submit manuscript

The Original Article was published on 30 April 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hoekstra PJ, Buitelaar JK (2016) Is the evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder flawed? Eur Child Adolesc Psychiatry 25(4):339–340

    Article  PubMed  Google Scholar 

  2. Sterne JA (2013) Why the Cochrane risk of bias tool should not include funding source as a standard item. Cochrane Database Syst Rev 12

  3. Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C (2015) Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. doi:10.1002/14651858.CD009885.pub2

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Child and Adolescent Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

    Pieter J. Hoekstra

  2. Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, and Karakter Child and Adolescent Psychiatry University Centre, Nijmegen, The Netherlands

    Jan K. Buitelaar

Authors
  1. Pieter J. Hoekstra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan K. Buitelaar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pieter J. Hoekstra.

Ethics declarations

Conflict of interest

Pieter J. Hoekstra has been a member of the advisory board of Shire. Jan K Buitelaar has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Janssen Cilag BV, Eli Lilly, Lundbeck, Shire, Roche, Medice, Novartis, and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoekstra, P.J., Buitelaar, J.K. Response to: The evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder is in fact flawed. Eur Child Adolesc Psychiatry 25, 1039–1040 (2016). https://doi.org/10.1007/s00787-016-0856-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00787-016-0856-z

Keywords

Search

Navigation